On 2014 Aug 12, Miguel Lopez-Lazaro commented:

In this article, my team assessed the in vitro cancer therapeutic potential of the compounds using a colorectal cancer cell line (HT29). We observed that several compounds improved the cytotoxic potency of the anticancer drug 5-fluorouracil; the IC50 value of the five most cytotoxic compounds was between 0.36 and 1.48 micromolar, and the IC50 value of 5-Fluroracil was 4.32 micromolar. Because our compounds killed cancer cells at lower concentrations that those of this commonly used anticancer drug, we discussed that they could have therapeutic potential.

More recently, we assessed the cytotoxic potency of these five compounds against lung cancer cells (A549) and lung nonmalignant cells (MRC5). Their IC50 values were between 0.96 and 4.31 micromolar in the cancer cell line and between 1.24 and 3.11 micromolar in the nonmalignant cell line. Some of the compounds were in fact more cytotoxic against the nonmalignant cell line.

Considering these new results, I think that the potential of these compounds for the treatment of colorectal cancer and lung cancer is low. I also think that my experimental design was unable to reveal their cancer therapeutic potential. To properly assess therapeutic potential using in vitro experiments one should use the most suitable experimental conditions to answer the following question:

Can my compounds improve the ability of the standard drugs to kill cancer cells without significantly affecting nonmalignant cells from a variety of appropriate tissues? (1)

Unfortunately, we did not address this question in our article.

Dr. Lopez-Lazaro

(1) Lopez-Lazaro, M. Experimental Cancer Pharmacology for Researchers: At What Concentration Should my Drug Kill Cancer Cells so that it has Potential for Cancer Therapy? 2014, ASIN: B00MMO25NM http://www.amazon.com/Experimental-Cancer-Pharmacology-Researchers-Concentration-ebook/dp/B00MMO25NM/ref=sr_1_1?ie=UTF8&qid=1407829198&sr=8-1&keywords="at+what+concentrations+should"

On 2014 Aug 12, Miguel Lopez-Lazaro commented:

In this article, my team assessed the in vitro cancer therapeutic potential of the compounds using a colorectal cancer cell line (HT29). We observed that several compounds improved the cytotoxic potency of the anticancer drug 5-fluorouracil; the IC50 value of the five most cytotoxic compounds was between 0.36 and 1.48 micromolar, and the IC50 value of 5-Fluroracil was 4.32 micromolar. Because our compounds killed cancer cells at lower concentrations that those of this commonly used anticancer drug, we discussed that they could have therapeutic potential.

More recently, we assessed the cytotoxic potency of these five compounds against lung cancer cells (A549) and lung nonmalignant cells (MRC5). Their IC50 values were between 0.96 and 4.31 micromolar in the cancer cell line and between 1.24 and 3.11 micromolar in the nonmalignant cell line. Some of the compounds were in fact more cytotoxic against the nonmalignant cell line.

Considering these new results, I think that the potential of these compounds for the treatment of colorectal cancer and lung cancer is low. I also think that my experimental design was unable to reveal their cancer therapeutic potential. To properly assess therapeutic potential using in vitro experiments one should use the most suitable experimental conditions to answer the following question:

Can my compounds improve the ability of the standard drugs to kill cancer cells without significantly affecting nonmalignant cells from a variety of appropriate tissues? (1)

Unfortunately, we did not address this question in our article.

Dr. Lopez-Lazaro

(1) Lopez-Lazaro, M. Experimental Cancer Pharmacology for Researchers: At What Concentration Should my Drug Kill Cancer Cells so that it has Potential for Cancer Therapy? 2014, ASIN: B00MMO25NM http://www.amazon.com/Experimental-Cancer-Pharmacology-Researchers-Concentration-ebook/dp/B00MMO25NM/ref=sr_1_1?ie=UTF8&qid=1407829198&sr=8-1&keywords="at+what+concentrations+should"